Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современная клиническая практика: применение цефдиторена пивоксила – нового цефалоспорина III поколения для приема внутрь - Справочник поликлинического врача №1 (2016)
Современная клиническая практика: применение цефдиторена пивоксила – нового цефалоспорина III поколения для приема внутрь
В.Б.Белобородов. Современная клиническая практика: применение цефдиторена пивоксила – нового цефалоспорина III поколения для приема внутрь. Справочник поликлинического врача. 2016; 1: 14-19.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Полный текст
Список литературы
1. Fenoll A, Granizo JJ, Aguilar L et al. Temporal trends of invasive Streptococcus pneumonia serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007.
J Clin Microbiol 2009; 47 (4): 1012–20.
2. Fenoll A, Aguilar L, Vicioso MD et al. Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumonia isolates from middle earfluidin a passive laboratory-based surveillance in Spain, 1997–2009. BMC Infect Dis 2011; 11: 239.
3. Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004). Int J Antimicrob Agents 2008; 31 (3): 245–9.
4. Калиногорская О.С., Беланов С.С., Волкова М.О. и др. Резистентность к антибиотикам и серотипы Streptococcus pneumoniae, выделенных у детей в Санкт-Петербурге в 2010–2013 годах. Антибиотики и химиотерапия. 2015; 60 (1–2): 10–8.
5. Granizo JJ, Giménez MJ, Barberán J et al. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioter 2008; 21 (1): 14–21.
6. Barberán TM, del Álamo OP, Pueyo MJ et al. Diagnosis and treatment of acute rhinosinusitis: second consensus. Rev Esp Quimioter 2008; 21 (1): 45–59.
7. Poachanukoon O, Kitcharoensakkul M. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial. Clin Ther 2008; 30 (10): 1870–9.
8. Ozaki T, Nishimura N, Suzuki M et al. Five-dayoral cefditoren pivoxilversus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis. J Infect Chemother 2008; 14 (3): 213–8.
9. Poachanukoon O, Tangsathapornpong A, Tanuchit S. A Comparison of Cefditoren Pivoxil 8–12 mg/kg/day and Cefditoren Pivoxil 16–20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, InvestigatorBlinded, ParallelGroup Study. Clin Exp Otorhinolaryngol 2015; 8 (2): 129–35.
10. Fogarty ChM, Cyganowski M, Palo WA et al. A Comparison of Cefditoren Pivoxil and Amoxicillin/Clavulanate in the Treatment of Community-Acquired Pneumonia: A Multicenter, Prospective, Randomized, Investigator-Blinded, Parallel-Group Study. Clin Ther 2002; 24: 1854–70.
11. AlvarezSala JL, Kardos P, Martínez-Beltrán J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditorenpivoxil versus cefuroximeaxetil. Antimicrob Agents Chemother 2006; 50 (5): 1762–7.
12. Blasi F, Tarsia P, Mantero M et al. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther Clin Risk Manag 2013; 9: 55–64.
13. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359 (22): 2355–65.
14. Chiba S, Ohta H, Abe K et al. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis incombined pulmonary fibrosis and emphysema. Pulm Med 2012; 2012: 492960.
15. Arai S, Kurasawa K, Maezawa R et al. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol 2012. [Epub ahead of print.]
16. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012; 50 (1): 3–13.
17. Granizo JJ, Gimnez MJ, Barber J et al. The Efficacy of Cefditoren Pivoxilin the Treatment of Lower Respiratory Tract Infections, with a Focus on the Per-Pathogen Bacteriologic Response in Infections Caused by Streptococcus pneumonia and Haemophilus influenzae: A Pooled Analysis of Seven Clinical Trials. Clin Ther 2006; 12 (28): 2061–9.
18. DiMarco F, Braido F, Santus P et al. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur Rev Med Pharm Sci 2014; 18: 321–32.
J Clin Microbiol 2009; 47 (4): 1012–20.
2. Fenoll A, Aguilar L, Vicioso MD et al. Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumonia isolates from middle earfluidin a passive laboratory-based surveillance in Spain, 1997–2009. BMC Infect Dis 2011; 11: 239.
3. Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004). Int J Antimicrob Agents 2008; 31 (3): 245–9.
4. Калиногорская О.С., Беланов С.С., Волкова М.О. и др. Резистентность к антибиотикам и серотипы Streptococcus pneumoniae, выделенных у детей в Санкт-Петербурге в 2010–2013 годах. Антибиотики и химиотерапия. 2015; 60 (1–2): 10–8.
5. Granizo JJ, Giménez MJ, Barberán J et al. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioter 2008; 21 (1): 14–21.
6. Barberán TM, del Álamo OP, Pueyo MJ et al. Diagnosis and treatment of acute rhinosinusitis: second consensus. Rev Esp Quimioter 2008; 21 (1): 45–59.
7. Poachanukoon O, Kitcharoensakkul M. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial. Clin Ther 2008; 30 (10): 1870–9.
8. Ozaki T, Nishimura N, Suzuki M et al. Five-dayoral cefditoren pivoxilversus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis. J Infect Chemother 2008; 14 (3): 213–8.
9. Poachanukoon O, Tangsathapornpong A, Tanuchit S. A Comparison of Cefditoren Pivoxil 8–12 mg/kg/day and Cefditoren Pivoxil 16–20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, InvestigatorBlinded, ParallelGroup Study. Clin Exp Otorhinolaryngol 2015; 8 (2): 129–35.
10. Fogarty ChM, Cyganowski M, Palo WA et al. A Comparison of Cefditoren Pivoxil and Amoxicillin/Clavulanate in the Treatment of Community-Acquired Pneumonia: A Multicenter, Prospective, Randomized, Investigator-Blinded, Parallel-Group Study. Clin Ther 2002; 24: 1854–70.
11. AlvarezSala JL, Kardos P, Martínez-Beltrán J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditorenpivoxil versus cefuroximeaxetil. Antimicrob Agents Chemother 2006; 50 (5): 1762–7.
12. Blasi F, Tarsia P, Mantero M et al. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther Clin Risk Manag 2013; 9: 55–64.
13. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359 (22): 2355–65.
14. Chiba S, Ohta H, Abe K et al. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis incombined pulmonary fibrosis and emphysema. Pulm Med 2012; 2012: 492960.
15. Arai S, Kurasawa K, Maezawa R et al. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol 2012. [Epub ahead of print.]
16. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012; 50 (1): 3–13.
17. Granizo JJ, Gimnez MJ, Barber J et al. The Efficacy of Cefditoren Pivoxilin the Treatment of Lower Respiratory Tract Infections, with a Focus on the Per-Pathogen Bacteriologic Response in Infections Caused by Streptococcus pneumonia and Haemophilus influenzae: A Pooled Analysis of Seven Clinical Trials. Clin Ther 2006; 12 (28): 2061–9.
18. DiMarco F, Braido F, Santus P et al. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur Rev Med Pharm Sci 2014; 18: 321–32.
Авторы
В.Б.Белобородов
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.